Calcium Current in Human Heart Cells

This study is currently recruiting participants.
Verified October 2013 by Emory University
Sponsor:
Information provided by (Responsible Party):
Mary Wagner, Emory University
ClinicalTrials.gov Identifier:
NCT00243776
First received: October 24, 2005
Last updated: October 31, 2013
Last verified: October 2013
  Purpose

We will use small pieces of human hearts which are removed as part of a required surgical procedure to study how calcium ions pass through the membrane of heart cells in order to tell the heart cell how much force to contract with when the heart beats. We will also study the proteins and RNA of these pieces to determine how the newborn heart cells control their force of contraction differently from adult heart cells. Our hypothesis is that infant hearts have different regulation of calcium entry than adult hearts.


Condition
Congenital Heart Disease
Tetralogy of Fallot

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Calcium Current in Human Atrial Myocytes

Resource links provided by NLM:


Further study details as provided by Emory University:

Primary Outcome Measures:
  • calcium current measures [ Time Frame: At time of aquisition ] [ Designated as safety issue: No ]
    We will measure calcium currents and transients and modulation of calcium handling by activation of different pathways in isolated cells from waste tissue obtained at the time of surgical repair for CHD.


Biospecimen Retention:   Samples Without DNA

tissue obtained from surgical waste tissue


Estimated Enrollment: 600
Study Start Date: April 2005
Estimated Study Completion Date: July 2015
Estimated Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)
Detailed Description:

Extrapolating pharmacological and surgical therapies from adult (AD) studies to infant (INF) patients is problematic because the knowledge of cellular electrophysiology and molecular biology of human INF heart cells is limited. We have studied developmental differences in rabbit ventricular cells and now extend these studies to atrial and ventricular cells isolated from AD, young adult (YAD) or INF patients. SA 1: Developmental differences in transient outward current of atrial cells. We will extend our studies to isolated cells and tissue from YADs (age 14-20). In addition, several other accessory beta-subunits have been found in cardiac myocytes and may interact with Kv channels and regulate the function of these channels. We will determine relative amounts of these putative regulators of human atrial Ito to determine which correlate with developmental changes in Ito kinetics.SA2: Developmental differences in amplitude and regulation of calcium current in atrial cells. We hypothesize that INF atrial cells have tonic inhibition of adenylyl cyclase (and thus of ICa) mediated by inhibitory G proteins, possibly related to constitutive activity of the adenosine A1 receptor, and that, compared to AD or YAD cells, have greater sensitivity to inhibitors of phosphatases and phosphodiesterases, and that developmental changes in basal ICa amplitude and beta-sympathetic modulation correlate with inhibitory G protein levels, receptor numbers for M2 and A1 receptors, and constitutive inhibitory activity. SA3: Modulation of atrial cell calcium transients by changes in AP waveform and developmental age. We will test the hypothesis that prolongation of the early repolarization phase of the AP increases Ca2+ entry and that YAD cells have faster removal of Ca2+ from cytoplasm than INF cells and we will determine if the Na- Ca2+ exchange current (INCX) is greater in INF vs. AD or YAD cells. SA4: Developmental differences in Ca current and transients in ventricular cells. We propose that INF cells and tissue have lower basal ICa, lower potency for ISO stimulation, higher levels of Gialpha3 and A1 receptors, greater inhibitory potency for adenosine, and tonic inhibition of ICa. We also propose that the YAD cells have lower levels of NCX and lower INCX, higher levels of SERCA and faster removal of Ca2+ from the cytoplasm. Previous animal studies have indicated various developmental changes in cardiac cells. We will specifically study human postnatal developmental changes in Ito, regulation of ICa and intracellular Ca2+ transients.

  Eligibility

Ages Eligible for Study:   up to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

children undergoing surgery for repair of congenital heart disease

Criteria

Inclusion Criteria:

patients undergoing cardiopulmonary bypass surgery

Exclusion Criteria:

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00243776

Contacts
Contact: Mary B Wagner, PhD 4047271336 mbwagne@emory.edu
Contact: Janet Fernandez, RN 4047851731 janet.fernandez@choa.org

Locations
United States, Georgia
Emory University School of Medicine Recruiting
Atlanta, Georgia, United States, 30322
Principal Investigator: Ronald w Joyner, M.D., Ph.D.         
Sponsors and Collaborators
Emory University
Investigators
Principal Investigator: Mary B Wagner, PhD Emory University
  More Information

No publications provided

Responsible Party: Mary Wagner, Principal Investigator, Emory University
ClinicalTrials.gov Identifier: NCT00243776     History of Changes
Other Study ID Numbers: IRB00005500, NIH R01HL077485
Study First Received: October 24, 2005
Last Updated: October 31, 2013
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Heart Diseases
Tetralogy of Fallot
Heart Defects, Congenital
Cardiovascular Diseases
Cardiovascular Abnormalities
Congenital Abnormalities

ClinicalTrials.gov processed this record on April 22, 2014